What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short answer

• The FDA moved to stop many compounding pharmacies and clinics that were making and selling compounded GLP‑1 products (semaglutide, tirzepatide, etc.) when those products were essentially copies of FDA‑approved drugs and were being produced or marketed outside the rules for compounding. The agency issued warning letters, seized some product, and told some firms to stop.
• That doesn’t mean all compounding activity is illegal — FDA‑approved manufacturers (Novo Nordisk, Eli Lilly) and licensed pharmacies dispensing prescribed, brand-name GLP‑1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, etc.) remain legal and regulated. Some compounding pharmacies can still operate legally if they meet strict, specific requirements (see below).

Important background (how compounding vs. approved drugs is regulated)

• FDA‑approved drugs are made by drug manufacturers under full FDA review and cGMP rules. Examples: Novo Nordisk’s semaglutide products (Ozempic, Wegovy) and Eli Lilly’s tirzepatide products (Mounjaro, Zepbound). Those are legal, tested, and distributed through licensed pharmacies and specialty pharmacies.
• Compounding pharmacies are allowed to make patient‑specific prescriptions under state pharmacy laws (so‑called 503A compounding). There are also 503B “outsourcing facilities” that can produce larger quantities but must register with FDA and follow stricter cGMP rules. Neither pathway authorizes making large‑scale copies of approved, commercially available drugs just to sell cheaper alternatives — that’s what triggered FDA enforcement.
• FDA enforcement focused on: making near‑identical copies of approved GLP‑1 drugs; interstate mass distribution without patient‑specific prescriptions; inadequate sterile compounding/quality controls; and unapproved marketing claims.

Who is still operating legally (categories and how to verify)

• FDA‑approved manufacturers and authorized distributors: Novo Nordisk and Eli Lilly (their branded GLP‑1 drugs) — these are fully legal and regulated. Use them if you want an FDA‑approved product with known dosing, labeling and safety information.
• Licensed prescribers and retail or specialty pharmacies (CVS, Walgreens, specialty pharmacy networks): legal channels for receiving prescribed, brand‑name GLP‑1s. These pharmacies follow cold‑chain, dispensing, and patient‑safety rules.
• Compounding pharmacies that follow the law:
  • 503A compounding pharmacies can legally compound only in response to an individual valid prescription and must comply with state board rules and USP standards (for sterile compounding). They typically shouldn’t be making batch copies of approved GLP‑1 drugs.
  • 503B outsourcing facilities that are registered with FDA and follow cGMP can legally operate, but FDA has made clear that compounding drugs that are essentially copies of available FDA‑approved GLP‑1 products is not acceptable absent a specific, legally allowed justification (for example, shortage or patient‑specific need).
• How to verify a compounding pharmacy is operating legally:
  • Check the pharmacy’s state board of pharmacy license (state lookup).
  • See if a 503B facility is on FDA’s registered outsourcing facility list.
  • Search the FDA Warning Letters and Enforcement Actions pages for the pharmacy name.
  • Ask the pharmacy for sterility testing results, USP <797>/<800> compliance, batch certificate of analysis, and accreditation (e.g., PCAB or ACHC). If they refuse or can’t provide documentation, walk away.

Risks of buying compounded GLP‑1s from questionable sources

• Variable potency, contamination, incorrect dosing, missing sterility testing, improper storage/handling (cold chain), and lack of pharmacovigilance. Also legal/financial risk if a product was produced illegally.

What you should do if you want GLP‑1 therapy

• Consult a licensed prescriber (PCP, endocrinologist, or board‑certified obesity medicine clinician). Ask for an FDA‑approved product first (Ozempic/Wegovy for semaglutide; Mounjaro/Zepbound for tirzepatide; Rybelsus for oral semaglutide). These are manufactured under FDA oversight.
• If cost or access is the issue, ask your clinician about insurance coverage, manufacturer savings programs (Novo Nordisk and Eli Lilly have patient assistance/copay programs), or legitimate specialty pharmacy options — don’t rely on unidentified internet vendors or clinics offering cheap compounded vials shipped across state lines.

If you want up‑to‑the‑minute specifics

• I’m current through June 2024. FDA activity intensified before that date; since enforcement actions change quickly, check:
  • FDA Warning Letters / Enforcement Actions search,
  • FDA list of registered 503B outsourcing facilities,
  • your state board of pharmacy license lookup,
  • recent news coverage from reliable outlets or your state attorney general’s consumer alerts.

If you want, I can:

• Look up what “legal to use” means in your state (tell me the state), or
• Walk you through how to verify a particular compounding pharmacy’s status (give me the pharmacy name).